HI SB3199

Establishes a 13-member Mental Health Emerging Therapies Task Force housed within an entity with scientific research and pharmaceutical/medical education expertise to prepare Hawaii for FDA-approved breakthrough therapies including MDMA-assisted therapy for PTSD and psilocybin for treatment-resistant depression.

Task force members include representatives from University of Hawaii schools, Department of Health divisions, Attorney General's office, Office of Wellness and Resilience, plus veterans, Native Hawaiian health organizations, psychiatrists, and community members with lived experience.

Requires the task force to develop a statewide implementation roadmap, identify clinical trial expansion opportunities, recommend workforce training pathways, and evaluate best practices for patient safety and culturally-informed care.

Mandates the Board of Pharmacy to reschedule or deschedule breakthrough therapy drugs within 90 days of any federal scheduling changes published in the Federal Register.

Task force must submit an interim report before the 2027 legislative session and a final report before the 2028 session; the Act sunsets June 30, 2028, with an effective date of January 30, 2050.